Prof Stephen Tait, Prof O Sansom
No more applications being accepted
Funded PhD Project (European/UK Students Only)
About the Project
The best way to treat cancer is to kill it - along these lines, many cancer treatments work by triggering apoptosis. While effective, cell death based therapies often fail due to incomplete killing that allows tumour outgrowth. Additionally, sub-lethal apoptotic signalling by cancer therapy can cause unwanted DNA-damage in normal cells. Importantly, our recent data shows that killing cancer cells in the presence of caspase inhibitors prevents unwanted DNA-damage and makes the dying cell stimulate anti-tumour immunity. Excitingly, this often leads to complete tumour regression.
Stemming from our findings, this PhD project will address two key questions: 1) how does killing cancer cells in caspase-deficient conditions make them immunogenic? 2) in which tumour-types can we exploit this type of cell killing as a therapeutic approach? To address these questions this PhD will apply a variety of cutting-edge approaches including live-cell microscopy, CRISPR/Cas9 genome editing and in vivo cancer models.
MVLS COLLEGE STUDENTSHIPS 2017
This is one of 10 fully funded studentship positions in the College of Medical Veterinary, Medical and Life Sciences. Projects are available from each of the research institutes within the College. Our next intake will be for PhD projects commencing October 2017.
The positions are fully funded for 3.5 years, and includes an annual consumable allowance.
All projects can be viewed here: http://www.gla.ac.uk/colleges/mvls/graduateschool/mvlscollegestudentships/projects/ - NOTE: DETAIL WITHIN STEP 6 OF APPLICATION PROCESS THE SUPERVISOR AND PROJECT TITLE.
Supervisors:
Dr Stephen Tait - [Email Address Removed]
Prof Owen Sansom - [Email Address Removed]
Funding Notes
3.5 year fully funded studentships (annual stipend and fees - RCUK rate)
Details on 'How to Apply' are available here: http://www.gla.ac.uk/colleges/mvls/graduateschool/mvlscollegestudentships/
References
Nat Rev Cancer. 2016,16:539-48; Nat Commun. 2016, 7:10538; Mol Cell. 2015, 57:860-72; Br J Cancer. 2015, 112:957-62.